NASDAQ:CHMAChiasma Stock Price, Forecast & News

Chiasma's stock was trading at $3.92 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CHMA shares have increased by 59.9% and is now trading at $6.27. View which stocks have been most impacted by Coronavirus.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chiasma in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Chiasma.

Chiasma is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Chiasma.

Chiasma Inc (NASDAQ:CHMA) announced its quarterly earnings results on Thursday, May, 7th. The biotechnology company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by $0.05. View Chiasma's earnings history.

5 Wall Street analysts have issued 1-year price objectives for Chiasma's stock. Their forecasts range from $10.00 to $18.00. On average, they expect Chiasma's share price to reach $13.00 in the next twelve months. This suggests a possible upside of 107.3% from the stock's current price. View analysts' price targets for Chiasma.

News articles about CHMA stock have trended somewhat negative this week, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Chiasma earned a news sentiment score of -1.6 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 6.0 out of 10, indicating that recent press coverage is somewhat likely to have an impact on the company's share price in the next few days. View the latest news aboutChiasma.

Chiasma saw a decrease in short interest in April. As of April 30th, there was short interest totaling 1,540,000 shares, a decrease of 24.9% from the April 15th total of 2,050,000 shares. Based on an average daily volume of 325,100 shares, the days-to-cover ratio is currently 4.7 days. Approximately 5.0% of the company's shares are short sold. View Chiasma's Current Options Chain.

Some companies that are related to Chiasma include Passage Bio (ORIC), Enanta Pharmaceuticals (ENTA), Rocket Pharmaceuticals (RCKT), Applied Therapeutics (APLT), Athenex (ATNX), BioXcel Therapeutics (BTAI), Rhythm Pharmaceuticals (RYTM), Amphastar Pharmaceuticals (AMPH), Stoke Therapeutics (STOK), Gossamer Bio (GOSS), Endo International (ENDP), Cue Biopharma (CUE), ImmunoGen (IMGN), Omeros (OMER) and Arcturus Therapeutics (ARCT). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Chiasma investors own include Arbutus Biopharma (ABUS), Bausch Health Companies (BHC), GW Pharmaceuticals PLC- (GWPH), BioDelivery Sciences International (BDSI), Viking Therapeutics (VKTX), Alnylam Pharmaceuticals (ALNY), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Exelixis (EXEL) and Progenics Pharmaceuticals (PGNX).

(CHMA) raised $76 million in an initial public offering (IPO) on Thursday, July 16th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. Barclays and Cowen and Company served as the underwriters for the IPO and William Blair and Oppenheimer & Co. were co-managers.

Chiasma trades on the NASDAQ under the ticker symbol "CHMA."

Chiasma's stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.04%), Ikarian Capital LLC (4.91%), Rock Springs Capital Management LP (3.19%), Vivo Capital LLC (3.01%), Stonepine Capital Management LLC (1.76%) and State Street Corp (1.47%). Company insiders that own Chiasma stock include Mark J Fitzpatrick, Roni Mamluk, Scott Minick and William Ludlam. View institutional ownership trends for Chiasma.

CHMA stock was sold by a variety of institutional investors in the last quarter, including Squarepoint Ops LLC, WINTON GROUP Ltd, JPMorgan Chase & Co., UBS Group AG, and Deutsche Bank AG. View insider buying and selling activity for Chiasma.

CHMA stock was purchased by a variety of institutional investors in the last quarter, including Vivo Capital LLC, Ikarian Capital LLC, Stonepine Capital Management LLC, Rock Springs Capital Management LP, Geode Capital Management LLC, Los Angeles Capital Management & Equity Research Inc., Spark Investment Management LLC, and BlackRock Inc.. Company insiders that have bought Chiasma stock in the last two years include Mark J Fitzpatrick, Scott Minick, and William Ludlam. View insider buying and selling activity for Chiasma.

Shares of CHMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CHMA stock can currently be purchased for approximately $6.27.

Chiasma has a market capitalization of $265.00 million. The biotechnology company earns $-36,320,000.00 in net income (profit) each year or ($1.06) on an earnings per share basis. Chiasma employs 49 workers across the globe.

The official website for Chiasma is www.chiasmapharma.com.

Chiasma's mailing address is 140 Kendrick Street Building C East, Needham MA, 02494. The biotechnology company can be reached via phone at 617-928-5300 or via email at [email protected]